

## DAFTAR PUSTAKA

- Apra, C., Peyre, M., Kalamarides, M., Apra, C., Peyre, M., Kalamarides, M., Apra, C., Peyre, M. and Kalamarides, M., 2019. Current treatment options for meningioma To cite this version : HAL Id : hal-01992074 Current treatment options for meningioma. , 18(3).
- Bachir, S., Shah, S., Shapiro, S., Koehler, A., Mahammed, A., Samy, R.N., Zuccarello, M., Schorry, E. and Sengupta, S., 2021. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. *International Journal of Molecular Sciences*, 22(2), pp.1–12.
- Basile, M.S. et al., 2019. Differential modulation and prognostic values of immune-escape genes in uveal melanoma. *PLoS ONE*, 14(1), pp.1–16.
- Buccoliero, A.M., Castiglione, F., Degl’Innocenti, D.R., Gheri, C.F., Garbini, F., Taddei, A., Ammannati, F., Mennonna, P. and Taddei, G.L., 2007. NF2 gene expression in sporadic meningiomas: Relation to grades or histotypes real time-PCR study. *Neuropathology*, 27(1), pp.36–42.
- Buerki, R.A., Horbinski, C.M., Kruser, T., Horowitz, P.M., James, C.D. and Lukas, R. V., 2018. An overview of meningiomas. *Future Oncology*, 14(21), pp.2161–2177.
- Campbell, B.A., Jhamb, A., Maguire, J.A., Toyota, B. and Ma, R., 2009. Meningiomas in 2009. Controversies and future challenges. *American Journal of Clinical Oncology: Cancer Clinical Trials*, 32(1), pp.73–85.
- Cham, L.B., Adomati, T., Li, F., Ali, M. and Lang, K.S., 2020. CD47 as a Potential Target to Therapy for Infectious Diseases. *Antibodies (Basel, Switzerland)*, 9(3), p.44.
- Chamberlain, M.C., 2012. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. *Journal of Neuro-Oncology*, 107(2), pp.315–321.
- Chow, H.Y. et al., 2015. Group I Paks as therapeutic targets in NF2-deficient meningioma. *Oncotarget*, 6(4), pp.1981–1994.
- Delgado-López, P.D., Cubo-Delgado, E., González-Bernal, J.J. and Martín-Alonso, J., 2020. A Practical Overview on the Molecular Biology of Meningioma. *Current Neurology and Neuroscience Reports*, 20(12).
- Downes, K., Peralta, R., Silkiss, R. and Deshmukh, S., 2022. Sphenoid Wing Meningioma. *American Academy of Ophthalmology*. Terdapat di:

[https://eyewiki.aao.org/Sphenoid\\_Wing\\_Meningioma#cite\\_note-sherman13-11](https://eyewiki.aao.org/Sphenoid_Wing_Meningioma#cite_note-sherman13-11) [Accessed 30 July 2022].

- Eladl, E., Tremblay-Lemay, R., Rastgoo, N., Musani, R., Chen, W., Liu, A. and Chang, H., 2020. Role of CD47 in Hematological Malignancies. *Journal of Hematology and Oncology*, 13(1), pp.1–14.
- Erkan, E.P., Ströbel, T., Dorfer, C., Sonntagbauer, M., Weinhäusel, A., Saydam, N. and Saydam, O., 2019. Circulating tumor biomarkers in meningiomas reveal a signature of equilibrium between tumor growth and immune modulation. *Frontiers in Oncology*, 9(SEP), pp.1–9.
- Garzon-Muvdi, T., Bailey, D.D., Pernik, M.N. and Pan, E., 2020. Basis for Immunotherapy for Treatment of Meningiomas. *Frontiers in Neurology*, 11(August), pp.1–11.
- Goldbrunner, R. et al., 2016. EANO guidelines for the diagnosis and treatment of meningiomas. *The Lancet Oncology*, 17(9), pp.e383–e391.
- Gunadi, S.V., Suryanti, S. and Yohana, R., 2018. The Distribution of Meningioma in Dr. Hasan Sadikin General Hospital Bandung Period 2010–2013. *Althea Medical Journal*, 5(3), pp.157–160.
- Gupta, R., Mehta, A. and Wajapeyee, N., 2022. Transcriptional determinants of cancer immunotherapy response and resistance. *Trends in Cancer*, 8(5), pp.404–415.
- Han, S.J. et al., 2016. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. *Journal of Neuro-Oncology*, 130(3), pp.543–552.
- Hansson, C.M., Buckley, P.G., Grigelioniene, G., Piotrowski, A., Hellström, A.R., Mantripragada, K., Jarbo, C., Mathiesen, T. and Dumanski, J.P., 2007. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. *BMC Genomics*, 8.
- Hao, S. et al., 2019. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. *Journal of Neuro-Oncology*, 144(1), pp.11–20.
- Hou, L. et al., 2022. Targeted Intervention of NF2–YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC. *ACS Nano*, 16(4), pp.5807–5819.

- Huang, R.Y. et al., 2019. Imaging and diagnostic advances for intracranial meningiomas. *Neuro-Oncology*, 21, pp.144–161.
- Huntoon, K., Toland, A.M.S. and Dahiya, S., 2020. Meningioma: A Review of Clinicopathological and Molecular Aspects. *Frontiers in Oncology*, 10(October), pp.1–14.
- Janah, R., Rujito, L. and Wahyono, D.J., 2022. Correspondence of Meningioma Orbital Grading and Clinicopathological Features among Indonesian Patients. *Open Access Macedonian Journal of Medical Sciences*, 10(A), pp.1525–1531.
- Janah, R., Rujito, L. and Wahyono, D.J., 2022. Expressions of Progesterone Receptor of Orbital Meningiomas in Indonesia. *Asian Pacific journal of cancer prevention: APJCP*, 23(12), pp.4137–4143.
- Jiang, Z., Sun, H., Yu, J., Tian, W. and Song, Y., 2021. Targeting CD47 for cancer immunotherapy. *Journal of Hematology & Oncology*, 14(1), p.180.
- Kannapadi, N.V., Shah, P.P., Mathios, D. and Jackson, C.M., 2022. Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review. *Frontiers in Oncology*, 12, p.892004.
- Karsy, M., Azab, M.A., Abou-Al-Shaar, H., Guan, J., Eli, I., Jensen, R.L. and Ormond, D.R., 2018. Clinical potential of meningioma genomic insights: A practical review for neurosurgeons. *Neurosurgical Focus*, 44(6), pp.1–7.
- Kerr, K., Qualmann, K., Esquenazi, Y., Hagan, J. and Kim, D.H., 2018. Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. *Clinical Neurosurgery*, 83(6), pp.1107–1118.
- Lassie, N. and Supartoto, A., 2016. Progesterone Receptor Expression in Histopathological Subtypes of Benign Orbitocranial Meningiomas. *Ophthalmologica Indonesiana*, 42(1). Terdapat di: <http://ophthalmologica.perdami.or.id/index.php/journal/article/view/72> [Accessed 4 February 2024].
- Lee, Young Suk and Lee, Youn Soo, 2020. Molecular characteristics of meningiomas. *Journal of Pathology and Translational Medicine*, 54(1), pp.45–63.
- Liu, X. et al., 2023. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma. *Current Neuropharmacology*, 21(10), pp.2159–2173.

- Louis, D.N. et al., 2016. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, 131(6), pp.803–820.
- Lu, Q., Chen, X., Wang, S., Lu, Y., Yang, C. and Jiang, G., 2020. Potential New Cancer Immunotherapy: Anti-CD47-SIRP $\alpha$  Antibodies. *OncoTargets and Therapy*, Volume 13, pp.9323–9331.
- Magill, S.T., Vagefi, M.R., Ehsan, M.U. and McDermott, M.W., 2020. Sphenoid wing meningiomas. In *Handbook of Clinical Neurology*. Elsevier, pp. 37–43. Terdapat di:  
<https://linkinghub.elsevier.com/retrieve/pii/B9780128221983000264>  
[Accessed 21 April 2024].
- Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E. and Vecht, C., 2008. Meningioma. *Critical Reviews in Oncology/Hematology*, 67(2), pp.153–171.
- Mirian, C. et al., 2020. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: An individual patient data meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, 91(4), pp.378–387.
- Murata, Y., Saito, Y., Kotani, T. and Matozaki, T., 2018. CD47-signal regulatory protein  $\alpha$  signaling system and its application to cancer immunotherapy. *Cancer Science*, 109(8), pp.2349–2357.
- Nakamura, M., Roser, F., Jacobs, C., Vorkapic, P. and Samii, M., 2006. Medial sphenoid wing meningiomas: Clinical outcome and recurrence rate. *Neurosurgery*, 58(4), pp.626–638.
- Nassiri, F. et al., 2021. A clinically applicable integrative molecular classification of meningiomas. *Nature*, 597(7874), pp.119–125.
- Nunes, F.P., Merker, V.L., Jennings, D., Caruso, P.A., di Tomaso, E., Muzikansky, A., Barker, F.G., Stemmer-Rachamimov, A. and Plotkin, S.R., 2013. Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients. *PLoS ONE*, 8(3).
- Ogasawara, C., Philbrick, B.D. and Adamson, D.C., 2021. Meningioma: A review of epidemiology, pathology, diagnosis, treatment, and future directions. *Biomedicines*, 9(3).

- Olcucuoglu, E., Sirin, M.E., Aydog, G., Gazel, E., Tastemur, S. and Odabas, O., 2017. Relationship with immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor. *Central European Journal of Urology*. Terdapat di: <http://ceju.online/journal/2017/cd-bladder-tumor-immnhistochemical-stain-1357.php> [Accessed 29 August 2022].
- Ostrom, Q.T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C. and Barnholtz-Sloan, J.S., 2019. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. *Neuro-Oncology*, 21(Suppl 5), pp.v1–v100.
- Ostrom, Q.T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N.E., Kruchko, C. and Barnholtz-Sloan, J.S., 2013. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. *Neuro-Oncology*, 15(SUPPL.2).
- Pant, I., Chaturvedi, S., Sarma, P. and Singh, G., 2021. Histopathological Mapping of Meningiomas: A 10-year Retrospective Analysis. *Indian Journal of Neurosurgery*, 10(03), pp.203–209.
- Perry, A. et al., 2001. Aggressive Phenotypic and Genotypic Features in Pediatric and NF2-Associated Meningiomas: A Clinicopathologic Study of 53 Cases. *Journal of Neuropathology & Experimental Neurology*, 60(10), pp.994–1003.
- Petralia, M.C., Mazzon, E., Fagone, P., Russo, A., Longo, A., Avitabile, T., Nicoletti, F., Reibaldi, M. and Basile, M.S., 2019. Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma. *Molecules*, 24(13), p.2450.
- Petrilli, A.M. and Fernandez-Valle, C., 2016. Role of Merlin/NF2 Inactivation in Tumor Biology. *Oncogene*, 35(5), pp.537–548.
- Proctor, D.T., Patel, Z., Lama, S., Resch, L., van Marle, G. and Sutherland, G.R., 2019. Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. *OncImmunology*, 8(1), pp.1–12.
- Qi, Z.-Y., Shao, C., Huang, Y.-L., Hui, G.-Z., Zhou, Y.-X. and Wang, Z., 2013. Reproductive and Exogenous Hormone Factors in Relation to Risk of Meningioma in Women: A Meta-Analysis O. Y. Gorlova, ed. *PLoS ONE*, 8(12), p.e83261.
- Ragel, B. and Jensen, Randy L., 2003. Pathophysiology of meningiomas. *Seminars in Neurosurgery*, 14(3), pp.169–185.

- Rutland, J.W. et al., 2021. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. *Cancer Immunology, Immunotherapy*, 70(1), pp.169–176.
- Seizinger, B.R., de La Monte, S., Atkins, L., Gusella, J.F. and Martuza, R.L., 1987. Molecular genetic approach to human meningioma: Loss of genes and chromosome 22. *Proceedings of the National Academy of Sciences of the United States of America*, 84(15), pp.5419–5423.
- Shibuya, M., 2015. Pathology and molecular genetics of meningioma: Recent advances. *Neurologia Medico-Chirurgica*, 55(1), pp.14–27.
- Simon, M., Boström, J.P. and Hartmann, C., 2007. Molecular genetics of meningiomas: From basic research to potential clinical applications. *Neurosurgery*, 60(5), pp.787–798.
- Smith, M.J. et al., 2011. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset. *Journal of Medical Genetics*, 48(4), pp.261–265.
- Sun, C. et al., 2020. The Preferred Locations of Meningioma According to Different Biological Characteristics Based on Voxel-Wise Analysis. *Frontiers in Oncology*, 10, p.1412.
- Supartoto, A. et al., 2019. Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females. *Frontiers in Oncology*, 8, p.651.
- Supartoto A, Mahayana, I.T., Heriyanto, D.S., Sasongko, M.B., Respatika, D., Sakti, D.H. and Nurlaila, P.S., 2019. Neurofibromatosis type 2 gene mutation and progesterone receptor messenger RNA expression in the pathogenesis of sporadic orbitocranial meningioma. *International Journal of Ophthalmology*, 11(4).
- Venur, V.A., Santagata, S., Galanis, E. and Brastianos, P.K., 2018. New molecular targets in meningiomas: The present and the future. *Current Opinion in Neurology*, 31(6), pp.740–746.
- Wang, S., Liechty, B., Patel, S., Weber, J.S., Hollmann, T.J., Snuderl, M. and Karajannis, M.A., 2018. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. *Journal of Neuro-Oncology*, 138(1), pp.183–190.

- Wen, P.Y. and Huse, J.T., 2017. 2016 World Health Organization Classification of Central Nervous System Tumors. *CONTINUUM Lifelong Learning in Neurology*, 23(6, Neuro-oncology), pp.1531–1547.
- Whittle, I.R., Smith, C., Navoo, P. and Collie, D., 2004. Meningiomas. *Lancet (London, England)*, 363(9420), pp.1535–1543.
- Widodo, D., Andriani, R. and Haq, I.B.I., 2019. Pedoman nasional pelayanan kedokteran tumor otak. *Komite Penanggulangan Kanker Nasional*, pp.1–206.
- Wiemels, J., Wrensch, M. and Claus, E.B., 2010. Epidemiology and etiology of meningioma. *Journal of Neuro-Oncology*, 99(3), pp.307–314.
- Willingham, S.B., Volkmer, J.P., et al., 2012. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proceedings of the National Academy of Sciences of the United States of America*, 109(17), pp.6662–6667.
- Yang, Jiaying, Yao, Y., Tong, L., Zhu, Z., Wang, L. and Yang, Jinju, 2021. CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy. *European Journal of Inflammation*, 19, p.205873922110008.
- Yuan, J., Shi, X., Chen, C., He, H., Liu, L., Wu, J. and Yan, H., 2019. High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis. *Oncology Letters*, 18(3), pp.3249–3255.